Last year, Sepracor, the maker of sleeping pill Lunesta, announced it would reduce its sales and marketing expenses by $90-100 million in 2008, "including an anticipated reduction of approximately ...

Will Sepracor change its name to "Aptiom" on April 1? That's the speculation on CafePharma, where one anonymous commenter notes that the maker of the sleeping pill Lunesta, whose moth-filled ads ...

Sepracor investors got some depressing news today when Eli Lilly called off a deal that might have extended the patent on Prozac, one of Eli Lilly's blockbuster drugs. The announcement dragged ...

Sepracor will eliminate 300 sales force positions as part of a cost cutting plan to reduce expenses by $90 million-$100 million for 2008. “We have examined our sales organization in depth,” Adrian ...

Sepracor Inc. and Dainippon Sumitomo Pharma Co., an Osaka, Japan-based pharmaceutical company, announced today that Sepracor's name will be changed to Sunovion Pharmaceuticals Inc. in the United ...

Sepracor Inc. in Marlborough said it has dropped its clinical development of Soltara, the allergic rhinitis drug that was initially rejected by the FDA last year. Less-than-positive early results ...

BOSTON (CBS.MW) -- Shares of Sepracor Inc. jumped as much as 15 percent Thursday on the news that its sleep aid Lunesta had received U.S. regulatory approval, a milestone that should allow the ...

Sepracor Inc., a U.S. subsidiary of Japanese drug maker Dainippon Sumitomo Pharma Co. Ltd. (DSP), is changing its name to Sunovion Pharmaceuticals Inc. in the U.S., which will go into effect befor ...

Sepracor has entered a licensing deal with Bial for the development and commercialization of Bial’s anti-epileptic compound BIA 2-093 in the US and Canada. Under the terms of the deal, Sepracor will ...

NEW YORK Marlborough, Mass.-based pharmaceutical company Sepracor has shelled out $50 million for a Canadian drug manufacturer, Sepracor announced Tuesday. Sepracor bought Canada’s Oryx ...

MARLBOROUGH, Mass. (CBS.MW) - Sepracor Inc. rose from obscurity to become a Wall Street darling in the late '90s as investors bet that the company could capture a big piece of the lucrative market ...

Sepracor Inc. will cut 20% of its permanent workforce and refine its business model amid challenging economic conditions despite swinging to a fourth-quarter profit that topped Wall Street ...